PARIS--France's top drug maker Sanofi SA reported Thursday a 26% rise in third-quarter net profit, lifted by sales in emerging markets and new grdiscount nfl jerseys
The Paris-based pharmaceutical major said its net income attributable to equity holders stood at €2.03 billion (US$2.8 billion) in the quarter ended Sept. 30, compared with €1.61 billion in the same quarter last year.
Sanofi's business net profit--the term it uses for adjusted income excluding items such as impacts associated with acquisitions--for the third cheap nfl jerseys free shipping
quarter was €2.4 billion, down 3%, as new generic competition in the U.S. and Europe and adverse currency fluctuations hit earnings.
These results are in line with forecasts which expected the company to report a business net profit of €2.36 billion, according to a poll of 10 analysts conducted by Dow Jones Newswires.
Sales rose 5%, lifted by the inclusion of U.S. biotech firm Genzyme, which Sanofi acquired last February in an effort to widen its research net and boost its fledging new-products pipeline.
The company posted net sales of €8.75 billion in the third quarter ended September, compared with €8.34 billion a year ago. Genzyme sales rose 7% to €768 million.
Sanofi, which is struggling with patent expirations on its blockbuster drugs, has been extending its pharmaceutical business to growth areas such as emerging markets, vaccines, diabetes solutions, consumer health care, innovative products and animal health, in a Cheap NFL Jerseys
bid to become less dependent on patented medicines.
The group continues to expect its earnings per share to be 2% to 5% lower in 2011 than in 2010.
Sanofi shares ended down 0.3% Wednesday at €49.87. The stock has lost 1.8% in value over the past 12 months.http://clanimpact.forum-pro.in/t6-sanofi-profit-climbs-26